These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21414305)

  • 1. Analysis of glucagon-like peptide 1; what to measure?
    Heijboer AC; Frans A; Lomecky M; Blankenstein MA
    Clin Chim Acta; 2011 Jun; 412(13-14):1191-4. PubMed ID: 21414305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
    Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.
    Balkan B; Kwasnik L; Miserendino R; Holst JJ; Li X
    Diabetologia; 1999 Nov; 42(11):1324-31. PubMed ID: 10550416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
    Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
    Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions.
    Pala L; Ciani S; Dicembrini I; Bardini G; Cresci B; Pezzatini A; Giannini S; Mannucci E; Rotella CM
    Diabet Med; 2010 Jun; 27(6):691-5. PubMed ID: 20546289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.
    Dai H; Gustavson SM; Preston GM; Eskra JD; Calle R; Hirshberg B
    Diabetes Obes Metab; 2008 Jun; 10(6):506-13. PubMed ID: 18284437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
    Triplitt C; Wright A; Chiquette E
    Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretins: the novel therapy of type 2 diabetes.
    Thongtang N; Sriwijitkamol A
    J Med Assoc Thai; 2008 Jun; 91(6):943-54. PubMed ID: 18697398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M; Bunck MC; Heine RJ
    Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The scientific evidence: vildagliptin and the benefits of islet enhancement.
    Mathieu C
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():9-17. PubMed ID: 19385979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [DPP-IV inhibitors and GLP-1 analogues].
    Zettl H; Steinhilber D
    Pharm Unserer Zeit; 2010 Mar; 39(2):108-13. PubMed ID: 20196037
    [No Abstract]   [Full Text] [Related]  

  • 15. Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice.
    Riedel MJ; Lee CW; Kieffer TJ
    Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E936-44. PubMed ID: 19190262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease.
    Pols TW; Auwerx J; Schoonjans K
    Gastroenterol Clin Biol; 2010; 34(4-5):270-3. PubMed ID: 20444564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.
    Deacon CF; Holst JJ
    Int J Biochem Cell Biol; 2006; 38(5-6):831-44. PubMed ID: 16242377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite.
    Wewer Albrechtsen NJ; Asmar A; Jensen F; Törang S; Simonsen L; Kuhre RE; Asmar M; Veedfald S; Plamboeck A; Knop FK; Vilsbøll T; Madsbad S; Nauck MA; Deacon CF; Bülow J; Holst JJ; Hartmann B
    Am J Physiol Endocrinol Metab; 2017 Sep; 313(3):E284-E291. PubMed ID: 28420649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based therapy and type 2 diabetes.
    Hare KJ; Knop FK
    Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.